Novadiscovery, 1 Place Giovanni Verrazzano, 69009, Lyon, France.
Genmab US, Inc., 777 Scudders Mill Rd Bldg 2 4th Floor, Plainsboro, NJ, 08536, USA.
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):581-604. doi: 10.1007/s10928-024-09930-x. Epub 2024 Jun 21.
Quantitative predictive modeling of cancer growth, progression, and individual response to therapy is a rapidly growing field. Researchers from mathematical modeling, systems biology, pharmaceutical industry, and regulatory bodies, are collaboratively working on predictive models that could be applied for drug development and, ultimately, the clinical management of cancer patients. A plethora of modeling paradigms and approaches have emerged, making it challenging to compile a comprehensive review across all subdisciplines. It is therefore critical to gauge fundamental design aspects against requirements, and weigh opportunities and limitations of the different model types. In this review, we discuss three fundamental types of cancer models: space-structured models, ecological models, and immune system focused models. For each type, it is our goal to illustrate which mechanisms contribute to variability and heterogeneity in cancer growth and response, so that the appropriate architecture and complexity of a new model becomes clearer. We present the main features addressed by each of the three exemplary modeling types through a subjective collection of literature and illustrative exercises to facilitate inspiration and exchange, with a focus on providing a didactic rather than exhaustive overview. We close by imagining a future multi-scale model design to impact critical decisions in oncology drug development.
癌症生长、进展和个体对治疗反应的定量预测建模是一个快速发展的领域。来自数学建模、系统生物学、制药行业和监管机构的研究人员正在合作开发预测模型,这些模型可应用于药物开发,并最终应用于癌症患者的临床管理。大量的建模范例和方法已经出现,使得在所有子学科中进行全面综述变得具有挑战性。因此,评估基本设计方面的要求,并权衡不同模型类型的机会和局限性至关重要。在这篇综述中,我们讨论了三种基本类型的癌症模型:空间结构模型、生态模型和免疫系统重点模型。对于每种类型,我们的目标是说明哪些机制导致癌症生长和反应的可变性和异质性,从而使新模型的适当架构和复杂性更加清晰。我们通过主观收集文献和说明性练习来展示这三种典型建模类型中的每一种所涉及的主要特征,以促进灵感和交流,重点是提供一种教学性而不是详尽的概述。最后,我们设想一个未来的多尺度模型设计,以影响肿瘤药物开发中的关键决策。